Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Investing.com -- Hologic Inc . (NASDAQ:HOLX) reported better-than-expected second-quarter results but lowered its full-year earnings guidance, sending shares down 1.8% in after-hours trading.
The medical technology company posted adjusted earnings per share of $1.03, edging past analyst estimates of $1.02. Revenue came in at $1.01 billion, slightly above the consensus forecast of $1 billion and at the high end of the company’s guidance range.
Despite the quarterly beat, Hologic reduced its fiscal 2025 earnings outlook. The company now expects full-year adjusted EPS of $4.15 to $4.25, down from its previous forecast of $4.25 to $4.35 and below analyst expectations of $4.26.
"We delivered on our financial commitments in the second quarter," said Stephen P. MacMillan, Hologic’s Chairman, President and CEO. "Both revenue and non-GAAP EPS finished at the high ends of our guidance ranges, driven by our diagnostics and skeletal businesses, strong profitability, share buybacks and a slightly lower tax rate."
Revenue declined 1.2% YoY to $1.01 billion, or 0.5% on a constant currency basis. Excluding COVID-19 related sales, organic revenue decreased 1.4%, or 0.7% in constant currency.
The diagnostics segment saw revenue rise 0.8% to $453.6 million, while breast health revenue fell 7.4% to $356.2 million. Surgical revenue grew 4.2% to $162.5 million.
For the third quarter, Hologic forecasts adjusted EPS of $1.04 to $1.07 on revenue of $1 billion to $1.01 billion, below analyst estimates.
CFO Karleen Oberton cited tariffs and geopolitical conditions as reasons for the lowered full-year EPS guidance, while maintaining the company’s revenue outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.